CO
Coya Therapeutics, Inc.
COYA · NASDAQ
$4.95 +0.20% (+$0.01)
1M -1.41%
Market Cap $111.7M
P/E Ratio -
Div. Yield -
ROE 0.20%
Bulios Fair Price
$3.74
24.4% downside
Current Price
$4.95
Undervalued Fair Value Overvalued
According to Bulios Fair Price, COYA is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
50 /100
Fair P/S 13.92x
P/B 0.00x
P/E N/A
Growth
-
N/A EPS growth N/A
Book val. growth N/A
Rev. growth N/A
Profitability
20 /100
Weak Gross margin 99.91%
FCF margin 170,613.00%
Net margin 270.22%
Quality
1 /100
Poor ROIC 0.05%
Asset turnover 0.00x
ROE 0.20%
Debt
100 /100
Low Debt/Equity 0.00x
Current ratio 13.40x
Int. coverage N/A
Stability
61 /100
Moderate Beta 0.62x
Profitable years 0
EPS volatility 36.27%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about COYA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Arun Swaminathan
Employees
8
Headquarters
Houston
Upcoming events
11 NOV
Earnings
Upcoming earnings report